warning on relying on one major product9 Jan 2021 10:49
Sareum Holdings had a RNS on the 7th Jan stating that the FDA had given approval for FLT3
On the 8th Jan a late RNS at around 16.00pm was issued, that although approval had been granted, their Chinese partners had pulled the plug on any further trials
and that the £50,000 stage payments would stop.
Now this has left Sareum TRYING to find a new partner.
Luckily they still have their TYK2/JAK1 which they hope will make them millions
in royalties.
Shares slumped 30% ,but investors are still buying large quantities of shares for a recovery.